Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [<sup>68</sup>Ga]ABY-025 Affibody PET/CTJens Nørkær Sørensen, Henrik Lindman, Irina Velikyan et al.|Theranostics|2015Cited by 269
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the <sup>111</sup>In-ABY-025 Affibody MoleculeJens Sørensen, Henrik Lindman, Dan Sandberg et al.|Journal of Nuclear Medicine|2014Cited by 260
Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule <sup>68</sup>Ga-ABY-025 in Breast Cancer PatientsMattias Sandström, Mark Lubberink, K. Lindskog et al.|Journal of Nuclear Medicine|2016Cited by 111
Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECTDan Sandberg, Jens Sørensen, Vladimir Tolmachev et al.|European Journal of Nuclear Medicine and Molecular Imaging|2017Cited by 60
First clinical observations of HER2 specific [111In]ABY-025 metastatic detection capability in females with metastatic breast cancerDan Sandberg, Henrik Lindman, Anders Wennborg et al.|Unknown|2012Cited by 7